Essen Biotech

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Phase 1

Recruiting

Conditions: Brain Tumor
Brain Metastases
Brain Cancer
Glioma
Gliomas, Malignant
Glioblastoma
Meningioma

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-05

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06640582

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Phase 1

Recruiting

Conditions: Lung Cancer, Non-small Cell
Lung Cancer Recurrent
Lung Cancer
Lung Cancer Metastatic

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-05

Last Posted Date: 2024-10-15

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06538012

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Phase 1

Recruiting

Conditions: Stomach Cancer
Stomach Cancer Recurrent
Stomach Cancer, Adenocarcinoma
Esophageal Cancer
Esophageal Cancer Metastatic to Bone
Esophageal Cancer Metastatic to Lung
Esophageal Cancer Metastatic to Liver

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 75

Registration Number: NCT06532799

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Breast Carcinoma
Breast Cancer Triple Negative
Breast Cancer Metastatic

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06532812

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer
Colon Cancer
Rectum Cancer

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-07-31

Last Posted Date: 2024-11-05

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06530303

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Phase 1

Recruiting

Conditions: Autoimmune Diseases
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Acute
Sjogren's Syndrome

Interventions: Biological: BCMA/CD19 CAR-T cells

First Posted Date: 2024-05-24

Last Posted Date: 2024-11-05

Lead Sponsor: Essen Biotech

Target Recruit Count: 60

Registration Number: NCT06428188

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

Phase 1

Recruiting

Conditions: T Cell Leukemia
T-cell Acute Lymphoblastic Leukemia
T-Cell Lymphoma of CNS
T Cell Lymphoma
T Cell Prolymphocytic Leukemia
T Cell Childhood ALL

Interventions: Biological: CD5/CD7 CAR-T

First Posted Date: 2024-05-17

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 60

Registration Number: NCT06420076

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
AML
AML, Adult
AML, Adult Recurrent

Interventions: Biological: CD123/CD33 CART

First Posted Date: 2024-05-17

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06420063

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle-Cell Disease With Crisis
Sickle Cell Disease

Interventions: Genetic: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan

First Posted Date: 2024-05-03

Last Posted Date: 2024-11-05

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06399107

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Phase 1

Recruiting

Conditions: Microscopic Polyangiitis
Sjogren's Syndrome
Lupus Nephritis
Systemic Lupus Erythematosus
Systemic Sclerosis
Autoimmune Diseases
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatous Polyangiitis
Idiopathic Inflammatory Myopathies

Interventions: Biological: CD19- BCMA CAR-T cells

First Posted Date: 2024-04-05

Last Posted Date: 2024-10-15

Lead Sponsor: Essen Biotech

Target Recruit Count: 75

Registration Number: NCT06350110

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy